Publications by authors named "Lelisse T Umeta"
Article Synopsis
- B-cell chronic lymphocytic leukemia (CLL) is driven by genetic defects and environmental factors that promote survival signals for CLL cells, making it challenging to treat and manage effectively.
- Novel small-molecule therapies, particularly SRX3305, target multiple pathways in CLL, showing promise in reducing cell proliferation and encouraging cell death while also addressing issues of drug resistance and toxicity associated with combination therapies.
- SRX3305 demonstrates effective inhibition of CLL cell migration and survival signals in the microenvironment, suggesting its potential as a promising therapeutic option for treating CLL, especially in patients resistant to existing treatments like ibrutinib.
